A phase 1/2a study shows that human neural progenitor cells modified to release the growth factor GDNF are safely transplanted into the spinal cord of patients with ALS, with cell survival and GDNF production for over 3 years.
- Robert H. Baloh
- J. Patrick Johnson
- Clive N. Svendsen